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Table 1
Characteristics of Patients with Graft Failure
Pt Diagnosis 1st graft Conditioning
1st graft
Graft
failure
Chimerism
CD3%/CD33%
2nd graft Same
than 1st
graft
Conditioning
2nd graft
Poor
graft
function
Chimerism
CD3%/CD33%
Outcome
from 2nd
graft
1 Post-ET MF VUD 10/10 Flu/Mel 2ry 10/98 VUD 10/10 no Flu/Cy/TBI200 no 100/100 Died, GVHD
2 Post-PV MF MMRD 9/10 Flu/Mel 1ry N/A VUD 9/10 yes Flu/Cy/TBI200 no 100/100 Alive 58 mo
3 PMF VUD 10/10 Flu/Mel/rATG 1ry N/A VUD 10/10 yes Flu/TBI200 yes 100/100 Died, GVHD
4 PMF
transformed
to AML
VUD 9/10 Flu/Bu/rATG 1ry N/A VUD 10/10 no Flu/Mel/Thio no 100/100 Alive 9 mo
5 Post-PV MF VUD 10/10 Flu/Mel 2ry 76/0 N/A N/A N/A no N/A Died,
pneumonia
6 PMF VUD 9/10 (DQ) Flu/Bu/rATG 2ry 0/100 N/A N/A N/A yes N/A Alive 3 mo
RIC-HSCT for MF still counts with signiﬁcant hurdles including primary and secondary GF. Use of unrelated, mismatched donors, RIC conditioning, and in vivo T-
cell depletion are potential risk factors for GF. Highly immunosuppressive non-myeloablative conditioning combining ﬂudarabine and low dose TBI promotes a
successful engraftment and can be used to salvage these patients.
Re-transplantation following graft failure is feasible. Further studies regarding optimal conditioning regimens are needed.
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ripheral blood stem cell (PBSC) transplantation. RIC included
Flu/Bu (5 patients), Flu/Bu/rATG (4 patients), Flu/Mel (20
patients) and Flu/Mel/rATG (11 patients). GVHD prophylaxis
was administered as FK/MTX (38 patients), CSA/MTX (1 pa-
tient) and CSA/MMF (3 patients). Sixteen were related do-
nors, and 26 unrelated; 36 donors were 10/10 and 6 were 9/
10 HLA matched. A JAK2 inhibitor was administered to 19
patients prior to HSCT. Mean and median OS were 24 and 13
months (range 1-79). Seventeen patients survived more than
2 years, and 7 are alive >5 years from second transplant.
Neutrophil engraftment, median 13 days (range 10-40);
platelet engraftment, median 20 days (range 11-87) with 10
patients failing to engraft platelets. For acute GVHD, 25 pa-
tients developed grade II-IV, and 8 patients developed
chronic GVHD. Six patients (14%) developed GF (4 primary, 2
secondary).421
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Background: Acute erythroid leukemia (AEL) is a rare sub-
type of AMLwith a relatively poor prognosis. Allogeneic stem
cell transplant (alloSCT) improves the outcomes of AEL;
however, only a small number (19%) of patients are typically
able to receive alloSCT (Blood 2010; 115: 1985).
Method: We retrospectively analyzed the outcomes of pa-
tients diagnosed with AEL (May 2008-January 2014) at Uni-
versity of Massachusetts Medical Center with respect to
alloSCT.
Results: Fourteen patients (3 females) were identiﬁed, me-
dian age was 73.2 years (range, 27-91) at diagnosis, 5 (35.7%)
were over the age of 80 years. At diagnosis median white
blood cell count was 1700 cells/mcL (range, 600-11,700),
hemoglobin was 9 grams/dL (range, 7.7-12.2) and platelet
count was 56,000 cells/mcL (range, 11,000-166,000). Six
(42.8%) patients had high risk disease based on the karyo-
type, 5 (35.7%) were tested for FLT3 and NPM1 mutation and
all of them were negative. Two (14.2%) patients had a prior
history of MDS. As initial therapy 6 (42.8%) patients received
a hypomethylating agent, 5 (35.7%) received induction
chemotherapy with high dose cytarabine/mitoxanthrone. Six
(42.8%) patients underwent alloSCT after receiving a reduced
intensity conditioning regimen. All of themwere in complete
remission prior to transplant. Median time to transplant was
4.9 months (range, 2.6-7.3). One of the six (16.6%) patients
developed acute GVHD, and 3 (50%) had chronic GVHD.
The median OS was 16.7 months (range, 0-36.5) of all AEL
patients. Patients whowere able to undergo an alloSCT had a
superior overall survival of 33months compared to 7months
without transplant (p¼0.036).
Conclusion: Our institutional experience conﬁrms that sur-
vival of patients with AEL can be signiﬁcantly improved by
allogeneic stem cell transplantation. Investigation of strate-
gies that will enable more AEL patients to receive allogeneic
SCT are warranted.422
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Table
Healthcare Costs during the 2-Year Study Period: CMV and No CMV Cohorts
Costs categories (2013 USD) CMV
cohort
(N ¼113)
No CMV
cohort
(N ¼ 113)
Cost
difference
P-value
Total costs 586,416.0 305,462.1 280,953.9 <.0001
Medical costs 543,813.1 276,593.3 267,219.7 <.0001
Inpatient services costs 343,691.6 157,995.6 185,696.0 <.0001
Emergency room
services costs
4,555.3 5,404.2 -848.9 0.2860
Outpatient services costs 195,566.2 113,193.6 82,372.6 <.0001
Drug costs 42,602.9 28,868.7 13,734.2 0.0079
Subcategories of total costs
Antiviral drug costs 6,920.6 449.7 6,470.9 <.0001
CMV laboratory test costs 3,357.1 1,473.3 1,883.7 0.0002
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suppresses T lymphocyte activity, and is used for GVHD
prophylaxis. According to some reports, pre-engraftment
immune reactions (PIR) occur early after CBT. During PIR
phase, we often experience instability of blood concentration
of TAC, and need the dose of the drug adjusted accordingly.
There are no reports assessing changes in TAC concentration
during the PIR phase.
Patients and Methods: Between July 2003 and November
2013, 105 patients received single-unit cord blood trans-
plantation (CBT) at our institution. We analyzed data for 63
patients for whom only TAC was used for GVHD prophylaxis.
The conditioning regimen was myeloablative conditioning
regimen for 11 patients and reduced intensity conditioning
for 52 patients. We assumed that the blood concentration of
TAC would reach a steady state between days 5 to 7 and
would be proportional to the dose used. Thus, the average
concentration of days 5 to 7 was used as the reference value.
TAC dose was adjusted based on blood concentration and
patient body weight, and compared with the reference dose
until day 40. PIR was diagnosed based on the criteria set forth
by Wake et al.
Results: Engraftment was achieved in 59 patients (median,
day 25), and 46 developed PIR. The blood concentration of
TAC signiﬁcantly decreased in the PIR group on day 8 (P<
0.001), but not in non-PIR group. On days 8, 9, and 10, the
adjusted dose of TAC signiﬁcantly increased in the PIR group
(P<0.001, 0.001, and 0.003, respectively) corresponding to
the decreased blood concentration of TAC, but not in the non-
PIR group.
Conclusions: Decreased blood concentration of TAC and
increased requirement of TAC dose in the PIR phase were
observed. During the PIR phase, frequent check of the TAC
blood concentration and adjustment of the drug should be
performed. These phenomena are possibly associated with T
lymphocyte activation.423
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Background: Cytomegalovirus (CMV), a common opportu-
nistic infection among stem cell transplant recipients, is
associated with substantial morbidity and mortality. Limited
information is available regarding the economic conse-
quences of CMV disease among these patients. The current
study evaluated the incremental healthcare costs associated
with CMV disease among stem cell transplant recipients.
Methods: Adults with stem cell transplant were identiﬁed in
the Truven Health MarketScan database (Q1 2002-Q4
2011). Patients were required to have 2 years of continuous
enrollment following the transplantation. They were classi-
ﬁed into the CMV cohort if they had  1 observed CMV
diagnosis within the 2-year period after transplantation
(study period), or the No CMV cohort if they did not have any
CMV diagnosis during the entire observation period in the
database. Patients in the CMV cohort were matched 1:1 to
patients in the No CMV cohort in two steps. The ﬁrst stepwas
exact matching based on age strata, gender, relevant
comorbidities, year of transplantation, type of stem cell
transplant, and donor type. The second stepwas a propensity
score match based on region of residence, health plan type,relevant comorbidities, and baseline healthcare resource
utilization and costs. The costs in the study period were
compared between the twomatched cohorts usingWilcoxon
signed-rank tests.
Results: Among 189 stem cell transplant recipients with
CMV and 2,539 recipients without CMV, a total of 113
matched pairs were identiﬁed. The baseline characteristics
were comparable between the matched CMV and No CMV
cohorts. During the 2-year study period, the CMV cohort was
associated with signiﬁcantly higher costs across all cost
categories. The total costs were $586,416 in the CMV cohort
vs. $305,462 in the No CMV cohort (incremental cost of
$280,954, p < 0.0001). The majority of the differences were
attributable to the incremental medical costs, accounting for
w95% of the total incremental costs (Table).
Conclusions: Stem cell transplant recipients with CMV dis-
ease incurred signiﬁcantly higher healthcare costs, including
costs for CMV lab tests and antiviral drugs, than those
without CMV disease.424
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Introduction: Cytomegalovirus (CMV) causes signiﬁcant
morbidity and mortality after allogeneic hematopoietic stem
cell transplant (allo-HSCT). Factors associated with progres-
sion from CMV viremia to disease despite pre-emptive CMV
treatment are poorly deﬁned. We sought to identify risk
factors among adult allo-HSCT recipients.
Methods: Retrospective single-center case-control study.
The McGill University Health Centre SCT Program database
was used to identify adults receiving a ﬁrst allo-HSCT be-
tween January 1, 2006 and February 12, 2013, and who
experienced 1 episode of CMV viremia detected by poly-
merase chain reaction (PCR). Medical records of cases (CMV
disease) and controls (without disease) were reviewed for
the following data: characteristics of recipient, donor, stem
cell graft, transplant procedure, viremic episodes, steroid use
post-transplant, and occurrence of acute and/or chronic
GVHD post-transplant. For analysis, Fisher’s exact test or
Wilcoxon Rank Sum test (for categorical and continuous
variables, respectively) was used. Variables were selected for
